Human Erythropoietin Quantikine IVD ELISA Kit New

Catalog #: DEP00B Datasheet / COA / SDS

Human Erythropoietin Quantikine IVD ELISA Kit

Catalog #	Availability	Size / Price	Qty
DEP00B

Control Products Available

CEP01: Human Erythropoietin Quantikine IVD Control 1&2 (5 vials ea)

CEP03: Human Erythropoietin Quantikine IVD Control 3 (10 vials)

Save 15% on Select RUO Reagents. See Details.

2 Images

Product Details

Supplemental Products

Reviews

Summary Sample Values Recovery Linearity Data Examples Product Datasheets Preparation and Storage Background Related Research Areas

Human Erythropoietin Quantikine IVD ELISA Kit Summary

Assay Type

Solid Phase Sandwich ELISA

Format

96-well strip plate

Assay Length

4.5 hours (Benchtop), 2.5 hours (Shaker)

Sample Type & Volume Required Per Well

Serum (100 uL), EDTA Plasma (100 uL)

Sensitivity

0.6 mU/mL

Assay Range

2.5 - 200 mU/mL (Serum, EDTA Plasma)

Specificity

Natural and recombinant human Epo.

Cross-reactivity

< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.

Interference

Interference observed with other substances.

Sample Values

Erythropoietin concentrations were obtained from 123 normal individuals from the Minneapolis/St. Paul, Minnesota area. Using the nonparametric method for the analysis of reference values outlined in the NCCLS publication "How to Define, Determine, and Utilize Reference Intervals in the Clinical Laboratory" (NCCLS Document C28-P; Vol. 12, No. 2) the following reference ranges (2.5-97.5 percentile) were established for Epo in serum and EDTA plasma. Each testing laboratory should establish its own normal range.

Epo Normal Ranges

Serum EDTA plasma
3.3-16.6 mlU/mL 3.1-14.9 mlU/mL

Patients suffering from polycythemia rubra vera may have Epo concentrations within the normal range, whereas those suffering from secondary polycythemia may have elevated concentrations of serum Epo (1). Polycythemia rubra vera patients who undergo phlebotomy may have elevated serum Epo concentrations.

Patients suffering from most anemias will present with higher than normal concentrations of serum Epo, whereas those suffering from anemia associated with chronic renal failure may have serum Epo concentrations within the normal range of this assay (2). Anemic patients who receive transfusions may exhibit lower than expected serum Epo concentrations.

Abnormally high concentrations of serum Epo may also be observed in various other pathological states including renal neoplasms, benign tumors, polycystic kidney disease, renal cysts and hydronephrosis (3).

The results of this assay should be used in conjunction with information available from clinical evaluations and other diagnostic procedures.

Product Summary

The Quantikine IVD Human Epo ELISA uses a monoclonal antibody and polyclonal antibody conjugate in a sandwich ELISA format to provide a method that is quicker, more sensitive and more specific than the bioassay. The assay is designed to measure Epo levels in serum or plasma

Recovery

Recovery was estimated by adding recombinant human Epo at three different levels across the range of the assay into six plasma and six serum specimens. Mean percent recoveries are shown in the table below:

	Benchtop Protocol		Shaker Protocol
Specimen Type	Average % Recovery	Range	Average % Recovery	Range
Serum (n=6)	100	84-115	101	96-107
EDTA Plasma (n=6)	99	81-114	96	84-105

Linearity

To assess the linearity of the assay, samples spiked with high concentrations of Epo were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.

		Benchtop Protocol		Shaker Protocol
		Serum	EDTA Plasma	Serum	EDTA Plasma
1:2	Average % of Expected	111	110	105	109
1:2	Range (%)	106-118	104-118	99-109	101-117
1:4	Average % of Expected	109	106	102	105
1:4	Range (%)	100-123	94-122	94-113	95-119
1:8	Average % of Expected	105	99	96	98
1:8	Range (%)	93-123	92-118	89-106	89-114

Product Datasheets

Product Datasheet

COA

SDS

Preparation and Storage

Storage

Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Erythropoietin/EPO

Erythropoietin (Epo) is a 30-kDa, heavily glycosylated protein produced primarily by the kidney. It is the principal factor that regulates erythropoiesis. The production of Epo by kidney cells is increased in response to hypoxia or anemia. The cDNAs for Epo have been cloned from many species. The mature proteins from the various species are highly conserved, exhibiting greater than 80% sequence identity at the amino acid level.

The biological effects of Epo are mediated by the Erythropoietin receptor (Epo R). At the protein sequence level, the human Epo R is approximately 83% identical to the mouse protein. As a result of alternative splicing of the Epo R gene, cDNA clones encoding truncated soluble forms of Epo R have been found. Recombinant soluble Epo R binds Epo with high affinity and is a potent Epo antagonist.

Entrez Gene IDs:

2056 (Human); 13856 (Mouse); 24335 (Rat)

Alternate Names:

ECYT5; EP; EPO; epoetin; Erythropoietin; MGC138142; MVCD2